Vascepa vs Lisinopril
A side-by-side look at two cardiovascular medications advertised on TV. Informational only — not medical advice.
| US Vascepa | US Lisinopril | |
|---|---|---|
| Generic name | icosapent ethyl | lisinopril |
| Drug class | Omega-3 Fatty Acid (EPA) | ACE Inhibitor |
| Treats | High triglycerides, cardiovascular risk reduction | High blood pressure, heart failure |
| Category | Cardiovascular | Cardiovascular |
| Manufacturer | Amarin | Various (generic) |
| Year approved | 2012 | 1987 |
| FDA warning | No boxed warning | Black box warning |
| Est. TV ad spend | $90M | $1M |
| Common side effects | Atrial fibrillation, Bleeding risk, Joint pain, Swelling | Dry cough, Dizziness, High potassium, Headache |
Lisinopril
Frequently asked questions
Is Vascepa or Lisinopril better?
Neither is universally "better." Vascepa (icosapent ethyl) and Lisinopril (lisinopril) are both used for cardiovascular, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Vascepa and Lisinopril?
Vascepa is a Omega-3 Fatty Acid (EPA) made by Amarin, while Lisinopril is a ACE Inhibitor made by Various (generic). See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Vascepa has the larger estimated TV advertising budget of the two.